InCarda Therapeutics’ Series C Equity Financing

Wilson Sonsini Goodrich & Rosati advised InCarda Therapeutics, Inc. on the deal.

InCarda Therapeutics, Inc., a privately held biopharmaceutical company developing first-of-their-kind inhaled therapies for cardiovascular diseases, announced that it has raised $30 million through the first close of a Series C equity financing. The financing was led by an affiliate of Innoviva, Inc. and also included existing investors Deerfield Management, HealthCap, and Morningside Venture. Proceeds from the financing will be used primarily to fund the ongoing clinical development of InRhythm™ (flecainide for inhalation), the company’s lead program, for the treatment of a recent-onset episode of paroxysmal atrial fibrillation (PAF).

The Wilson Sonsini team that advised InCarda on IP matters related to this transaction includes Bruce Kisliuk (Picture), Wei Huang, and Ben Schwamb.

Involved fees earner: Wei Huang – Wilson Sonsini Goodrich & Rosati; Bruce Kisliuk – Wilson Sonsini Goodrich & Rosati; Ben Schwamb – Wilson Sonsini Goodrich & Rosati;

Law Firms: Wilson Sonsini Goodrich & Rosati;

Clients: InCarda Therapeutics;

Author: Ambrogio Visconti